XENE · Xenon Pharmaceuticals Inc.
$65.42
-1.28% last session
End-of-day data · updated 2026-07-28
Market cap
$6B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
-13.1
Dividend yield
—
Beta
0.61
Avg volume
1M
Employees
0K
2D change
—
5D change
0.55%
10D change
-3.63%
30D change
10.11%
60D change
20.19%
MTD change
9.09%
YTD change
46.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — XENE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-27
Latest call per bank · past 12 months
JP Morgan
Overweight$82.00
+25.3% vs priceRBC Capital
Outperform$82.00
+25.3% vs priceWells Fargo
Overweight$68.00
+3.9% vs priceDeutsche Bank
Buy$90.00
+37.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-27 | JP Morgan | Maintains | Overweight | $80.00 → $82.00 |
| 2026-05-12 | JP Morgan | Maintains | Overweight | $77.00 → $80.00 |
| 2026-05-08 | RBC Capital | Maintains | Outperform | $80.00 → $82.00 |
| 2026-05-08 | Needham | Maintains | Buy | $80.00 → $78.00 |
| 2026-03-16 | Wedbush | Maintains | Outperform | $64.00 → $63.00 |
| 2026-03-10 | Wells Fargo | Maintains | Overweight | $49.00 → $68.00 |
| 2026-03-10 | Wedbush | Maintains | Outperform | $47.00 → $64.00 |
| 2026-03-10 | Deutsche Bank | Maintains | Buy | $56.00 → $90.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.1% above the 50-day MA ($58.45).
- Price vs 200-day MA: Trading 30.8% above the 200-day MA ($49.66).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.58) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($30.30) and high ($70.96).
XENE Price Chart
Loading chart for XENE…
Fundamentals
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.